Earnings call transcript: Aehr Test Systems beats Q1 2026 estimates, raises outlook

Aehr Test Systems reported fiscal Q1 2027 revenue of $33 million, up 200% year over year and 23% above the $26.82 million estimate, while adjusted EPS of $0.28 beat the $0.10 consensus. Gross margin rose to 48.5% from 37.5%, bookings reached $46.7 million, and management raised full-year revenue guidance to $150 million from a prior range of $130 million to $150 million. Shares fell 6.23% in regular trading to $51.47, then rose 14.86% after hours to $59.12; management cited expanding AI-related demand but noted customer timing, execution and quarterly product-mix risks.

Analysis

The earnings beat matters less than whether Aehr can convert qualification work into repeat production demand. The key near-term execution test is the Taiwan production evaluation scheduled for early 2027: successful throughput, uptime and thermal-control validation could make wafer-level burn-in easier to adopt across other complex AI designs. Until that evidence arrives, management’s very large per-unit opportunity estimates are scenarios, not an order pipeline. The current-year outlook appears better supported by existing programs, but backlog is not equivalent to revenue: customer shipment schedules and qualification timing still govern conversion.

The mix creates a second-order margin risk. Management expects lower gross margin in Q2 as Sonoma systems weigh more heavily; a margin dip alone would not falsify demand, but persistent deterioration beyond the guided annual range would challenge the operating-leverage narrative. Consumables may support revenue as the installed base expands, though device-specific replacements and quarter-to-quarter mix make them less predictable than a subscription stream.

For TER, the article’s distinction between system-level testing and burn-in is relevant competitive context, not evidence of lost orders or share. TSM could benefit indirectly if screening reduces costly failures in advanced packages, but the article provides no basis to quantify that exposure.

Contrarian point: after-hours enthusiasm may be pricing the long-dated wafer-level opportunity before production qualification. The stock’s stated volatility makes chasing the gap unattractive; the risk is a sharp reset if evaluation timing slips or customer ramps move right.

Key Decisions for Investors

• AEHR: Do not chase the after-hours move. Consider only a small, staged position after regular-session price discovery if the post-report gain holds; use a close below the pre-report $51.47 close as a practical thesis-review trigger, not a price target.
• Treat the Taiwan evaluation as the principal 1–3 month-to-early-2027 catalyst. Track installation timing and independently verifiable production metrics—uptime, throughput, and customer follow-on orders—before underwriting the larger wafer-level opportunity.
• Watch Q2 gross margin and subsequent backlog conversion. A temporary mix-driven decline is consistent with management’s outlook; sustained weakness beyond the stated annual margin range, or delayed shipments/cancellations, would weaken the long thesis.
• No TER pair trade is warranted from this report alone: the stated competitive distinction is management’s framing, and no displacement or share-loss evidence is provided.